Arrowhead Pharmaceuticals (ARWR) +20% on $2B Novartis Deal
‍

Arrowhead surged 20% this week after striking a licensing agreement with Novartis worth up to $2 billion for its neuromuscular therapy program. The deal, which includes upfront payments and milestones, positions Arrowhead as a major player in next-generation RNAi therapeutics while giving Novartis expanded exposure to rare disease markets.

‍

vTv Therapeutics (VTVT) +21% on FDA Breakthrough Designation

‍
vTv jumped 21% in a single day after its diabetes drug candidate, Cadisegliatin, received Breakthrough Therapy designation from the FDA. The designation accelerates development and review timelines, underscoring the therapy’s potential to address unmet needs in diabetes treatment. The sharp move reflects investor enthusiasm for regulatory catalysts in small-cap biotech.

‍

Broadcom (AVGO) +9.4% on $10B+ OpenAI Chip Deal & Strong Earnings

‍

Broadcom shares rallied 9.4% to $334.89 after reporting a $10B+ order from OpenAI for custom AI accelerator chips, set to ship in 2026. The deal positions Broadcom as a strategic alternative to Nvidia in AI hardware, with OpenAI aiming to ease supply bottlenecks and tailor processors for its expanding model needs.
‍

For the quarter, revenue rose 22% YoY to nearly $16B, beating expectations ($15.8B), with EPS of $1.69 topping estimates. AI semiconductor sales hit $5.2B and are projected to climb to $6.2B in Q4. Broadcom also guided Q4 revenue to ~$17.4B, above consensus, while CEO Hock Tan extended his leadership through at least 2030.

‍

Culture Meets Earnings: American Eagle (AEO) +26% on Guidance Boost

‍

Last week we noted how cultural flashpoints — from the Sydney Sweeney denim ad to the Travis Kelce collaboration — had already lifted American Eagle shares. This week, earnings confirmed the impact: AEO soared 26% after reinstating full-year guidance well above expectations. Management now projects operating income of $255M–$265M (vs. $176M consensus) with same-store sales set to turn positive in the second half.
‍

Q2 results were mixed — revenue slipped 1% YoY to $1.28B and same-store sales fell 1% — but EPS of $0.45 more than doubled forecasts. The company credited early traction from the Sweeney and Kelce campaigns for boosting engagement and sales momentum heading into fall.
‍

The takeaway: cultural buzz has converted into real financial upside. With campaigns driving customer awareness and management guiding to stronger back-half performance, AEO has shifted from a retail controversy story into one of the quarter’s biggest retail rebound trades.

‍